Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study

Journal of Clinical Oncology

Volumn 25, Issue 17, 2007, Pages 2406-2413

  Garland, Linda L ^a   Rankin, Cathryn ^a   Gandara, David R ^a   Rivkin, Saul E ^a   Scott, Katherine M ^a   Nagle, Raymond B ^a   Klein Szanto, Andres J P ^a   Testa, Joseph R ^a   Altomare, Deborah A ^a   Borden, Ernest C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HEMOGLOBIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER GROWTH; CANCER PATIENT; CAUSE OF DEATH; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TARGETING; DRY EYE; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; KERATITIS; LEUKOPENIA; LUNG INFILTRATE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; RECTUM HEMORRHAGE; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; VOMITING; WEAKNESS; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 34347273808     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.7634     Document Type: Article

References (43)

1. Lanphear BP, Buncher CR: Latent period for malignant mesothelioma of occupational origin. J Occup Med 34:718-721, 1992
2. Peto J, Decarli A, La Vecchia C, et al: The European mesothelioma epidemic. Br J Cancer 79: 666-672, 1999
3. Martini N, McCormack PM, Bains MS, et al: Pleural mesothelioma. Ann Thorac Surg 43:113-120, 1987
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003
5. van Meerbeeck JP, Gaafar R, Manegold C, et al: Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23:6881-6889, 2005
6. Tysnes BB, Haugland HK, Bjerkvig R: Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Invasion Metastasis 17:270-280, 1997
7. Kari C, Chan TO, Rocha de Quadras M, et al: Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage. Cancer Res 63:1-5, 2003
8. Chen P, Xie H, Sekar M, et al: Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol 127:847-857, 1994
9. Alper O, Bergmann-Leitner ES, Bennett TA, et al: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93:1375-1384, 2001
10. Faux SP, Houghton CE, Hubbard A, et al: Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis 21:2275-2280, 2000
11. Lahat N, Froom P, Kristal-Boneh E, et al: Increased serum concentrations of growth factor receptors and Neu in workers previously exposed to asbestos. Occup Environ Med 56:114-117, 1999
12. Dazzi H, Hasleton PS, Thatcher N, et al: Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R): Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody. Br J Cancer 61:924-926, 1990
13. Janne PA, Taffaro ML, Salgia R, et al: Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: 5242-5247, 2002
14. Cole GW Jr, Alleva AM, Reddy RM, et al: The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg 129:1010-1017, 2005
15. Blackledge G, Averbuch S: Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer 90:566-572, 2004
16. Moore MJ: Brief communication: A new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32:5-6, 2005
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Steele JP, Shamash J, Evans M, et al: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917, 2000
19. Merritt N, Blewett CJ, Miller JD, et al: Survival after conservative (palliative) management of pleural malignant mesothelioma. J Surg Oncol 78:171-174, 2001
20. Govindan R, Kratzke RA, Herndon JE, et al: Gefitinib in patients with malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11:2300-2304, 2005
21. Byrne M, Nowak A: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260, 2004
22. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
23. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
24. Hirsch FR, Witta S: Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 17:118-122, 2005
25. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887, 2005
26. Cortese JF, Gowda AL, Wali A, et al: Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118:521-522, 2006
27. Tzahar E, Waterman H, Chen X, et al: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287, 1996
28. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
29. Cappuzzo F, Gregorc V, Rossi E, et al: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663, 2003
30. Horvai AE, Li L, Xu Z, et al: Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2. Arch Pathol Lab Med 127:465-469, 2003
31. Ascoli V, Scalzo CC, Nardi F: C-erbB-2 oncoprotein immunostaining in serous effusions. Cytopathology 4:207-218, 1993
32. Thirkettle I, Harvey P, Hasleton PS, et al: Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas. Histopathology 36:522-528, 2000
33. Janmaat ML, Kruyt FA, Rodriguez JA, et al: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316-2326, 2003
34. Magne N, Fischel JL, Dubreuil A, et al: Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 86:1518-1523, 2002
35. Han SW, Hwang PG, Chung DH, et al: Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 113:109-115, 2005
36. Bellacosa A, Kumar CC, Di Cristofano A, et al: Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 94:29-86, 2005
37. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98: 10983-10985, 2001
38. Cappuzzo F, Magrini E, Ceresoli GL, et al: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96:1133-1141, 2004
39. Pao W, Zakowski M, Cordon-Cardo C, et al: Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. J Clin Oncol 23:619, 2004 (suppl, abstr 7025)
40. Franklin WA, Chansky K, Gumerlock P, et al: Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC. J Clin Oncol 23:617, 2004 (abstr 7015)
41. Papp T, Schipper H, Pemsel H, et al: Mutational analysis of the PTEN/MMAC1 tumour suppressor gene in primary human malignant mesotheliomas. Oncol Rep 8:1375-1379, 2001
42. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-induced factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127, 2006
43. DeGraffenried LA, Fulcher L, Friedrichs WE, et al: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15:1510-1516, 2004